Aortic Valve Stenosis Clinical Trials

Find Aortic Valve Stenosis Clinical Trials Near You

CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia. This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \>18 years.

• Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m/s, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² \[or indexed aortic valve area (AVAi) ≤0.6 cm²/m²\].

• New York Heart Association (NYHA) functional class II or higher.

• Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

• Undergoing preoperative coronary computed tomography angiography (CCTA).

• Willing to participate in the study and able to provide written informed consent.

Locations
Other Locations
China
Yan'an Hospital Affiliated to Kunming Medical University
RECRUITING
Kunming
Contact Information
Primary
Xirui Duan
248190836@qq.com
+86 13294957739
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 300
Treatments
Experimental: CCTA + CT-FFR Group
Preoperative revascularization decision-making (TAVR/SAVR) is guided by both CCTA anatomical information and CT-FFR functional information.
Active_comparator: CCTA Group
Preoperative revascularization decision-making (TAVR/SAVR) is guided solely by CCTA anatomical information.
Sponsors
Leads: Yan'an Affiliated Hospital of Kunming Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials